Spyre reports positive Phase 2 trial results for ulcerative colitis drug SPY002

Filed June 15, 2026 · Period ending June 15, 2026 · ~1 min read

Key Changes

• high

  SPY002 met primary endpoint with 10.7-point reduction in disease severity score (p<0.0001), achieving 33% clinical remission and 42% endoscopic improvement—results the company says are among the highest reported in ulcerative colitis.

  Item 7.01 verify on EDGAR →
• high

  Trial enrolled challenging patient population with 35% having previously failed advanced therapies, suggesting SPY002 may work in treatment-resistant cases.

  Item 7.01 verify on EDGAR →
• high

  Safety profile was manageable with 41.7% experiencing adverse events, only 6.3% drug-related. Two serious adverse events occurred but were deemed unrelated to the drug, with no deaths reported.

  Item 7.01 verify on EDGAR →